2.Novo’s Older GLP-1 Drug Slows Cognitive Decline in Phase IIb Alzheimer’s Trial.July 30, 2024.Nick Paul Taylor 3.Novo's GLP-1 liraglutide may protect brain from Alzheimer's, new study finds.By Darren Incorvaia Jul 30, ...
https://www.biospace.com/drug-development/7-indications-for-glp-1s-beyond-weight-loss
目前,有分析师预测最快两年内GLP-1药物就会进入NASH市场。 要知道2024年12月10日,Nature旗下的Nature reviews drug discovery子刊上发布了一份生物企业简报,对2025年TOP 10 药物销售额进行了预测。TOP 10药物里面有四款都是GLP-1药物,且2025年司美格鲁肽销售额将超越K药成为新任全球药王。 仅仅依靠减肥与糖尿病两...
GLP-1药物是目前医药领域最热门的开发项目,除诺和诺德的Wegovy, Ozempic和礼来的Zepbound, Mounjaro之外;还有一系列GLP-1受体激动剂或者GLP-1受体共激动剂喷薄欲出,包括辉瑞的Danuglipron(小分子),阿斯利康的ECC5004(小分子), 礼来的retatrutide(多肽), 西兰制药和勃林格殷格翰的survodutide(多肽),以及Amgen的Mari...
[1] How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse. Retrieved October 24, 2023, from https://www.statnews.com/2023/10/17/lotte-knudsen-novo-nordisk-obesity-drug-liraglutide-ozempic-wegovy/ [2] Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide...
[1] GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years[J]. New England journal of medicine, 2017, 377(1): 13-27.[2] 中国居民营养与慢性病状况报告2020 [3] Müller T D, Blüher M, Tschöp M H, et al. Anti-obesity drug discovery:...
[1]https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00486-X#%20 [2]https://www.fiercebiotech.com/research/glp-1-drug-hydrogels-could-reduce-shots-once-every-4-months [3]https://news.stanford.edu/2023/11/21/drug-delivery-system-reduce-daily-diabetes-shots-just-three-...
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1
[9] Can Novo Nordisk's blockbuster weight loss drug and other GLP-1s also work in NASH? The answer is complicated. Retrieved September 8, 2023, from https://endpts.com/blind-spots-remain-in-semaglutide-and-other-glp-1s-bid-for-label-expansion-in-nash-experts-say/...
来源:Anti-obesity drug discovery: advances and challenges.Nature Reviews. 2.全球上市GLP-1药物 目前全球已上市多款GLP-1多肽类药物,包括每日注射产品(艾塞那肽、利拉鲁肽、利司那肽和贝那鲁肽等),周注射制剂(艾塞那肽微球、阿必鲁肽、度拉糖肽、司美格鲁肽、替尔泊肽和聚乙二醇洛塞那肽等)、以及口服司...